Renowned biotech specialist, venture capitalist, author and keynote speaker Mr. Burrill offers his predictions for biotech. He sees a dynamic industry writing a new "play book" in response to an environment that: favors risk mitigated companies rather than earlier stage development companies that have a much higher risk profile; emerging biotech markets, particularly in Brazil, Chile, China, India, Malaysia and Russia, growing faster than the United States and Europe; challenges created by healthcare reform; and opportunities for companies operating in the biogreentech space.
